Click here to get full coverage on XCUR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

XCUR Financials: Revenue Breakdown, Margins & Competitor Comparison  Intellectia AI

XCUR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Click here to get full coverage on Exicure (NASDAQ: XCUR) advances derivative case settlement with new governance controls - Stock Titan

Exicure (NASDAQ: XCUR) advances derivative case settlement with new governance controls  Stock Titan

Exicure (NASDAQ: XCUR) advances derivative case settlement with new governance controls - Stock Titan

Click here to get full coverage on Insider Sale: 10% owner at $XCUR Sells 433,332 Shares | XCUR Stock News - Quiver Quantitative

Insider Sale: 10% owner at $XCUR Sells 433,332 Shares | XCUR Stock News  Quiver Quantitative

Insider Sale: 10% owner at $XCUR Sells 433,332 Shares | XCUR Stock News - Quiver Quantitative

Click here to get full coverage on Exicure Reaches Preliminary Settlement in Derivative Lawsuits - TipRanks

Exicure Reaches Preliminary Settlement in Derivative Lawsuits  TipRanks

Exicure Reaches Preliminary Settlement in Derivative Lawsuits - TipRanks

Click here to get full coverage on Exicure HiTron Inc sells $3.3m in Exicure (XCUR) stock - Investing.com

Exicure HiTron Inc sells $3.3m in Exicure (XCUR) stock  Investing.com

Exicure HiTron Inc sells $3.3m in Exicure (XCUR) stock - Investing.com

Click here to get full coverage on Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions - Bitget

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions  Bitget

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions - Bitget

Click here to get full coverage on Exicure’s Risky Bet On Stem Cell Mobilization Pays Early Dividends - finimize.com

Exicure’s Risky Bet On Stem Cell Mobilization Pays Early Dividends  finimize.com

Exicure’s Risky Bet On Stem Cell Mobilization Pays Early Dividends - finimize.com

Click here to get full coverage on XCUR Should I Buy - Intellectia AI

XCUR Should I Buy - Intellectia AI

Click here to get full coverage on Exicure says its cash won't fund the next 12 months of operations - Stock Titan

Exicure says its cash won't fund the next 12 months of operations  Stock Titan

Exicure says its cash won't fund the next 12 months of operations - Stock Titan

Click here to get full coverage on Exicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional Financing - Quiver Quantitative

Exicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional Financing  Quiver Quantitative

Exicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional Financing - Quiver Quantitative

Click here to get full coverage on Liquidity strain deepens as Exicure (NASDAQ: XCUR) posts 2025 results - Stock Titan

Liquidity strain deepens as Exicure (NASDAQ: XCUR) posts 2025 results  Stock Titan

Liquidity strain deepens as Exicure (NASDAQ: XCUR) posts 2025 results - Stock Titan

Click here to get full coverage on Exicure, Inc. Reports 2025 Financial Results and Announces Need for Additional Financing - Quiver Quantitative

Exicure, Inc. Reports 2025 Financial Results and Announces Need for Additional Financing  Quiver Quantitative

Exicure, Inc. Reports 2025 Financial Results and Announces Need for Additional Financing - Quiver Quantitative

Click here to get full coverage on Exicure (XCUR) director Sangjin Yeo to leave board and Audit Committee - Stock Titan

Exicure (XCUR) director Sangjin Yeo to leave board and Audit Committee  Stock Titan

Exicure (XCUR) director Sangjin Yeo to leave board and Audit Committee - Stock Titan

Click here to get full coverage on Exicure (NASDAQ: XCUR) flags going concern, legal and listing risks - Stock Titan

Exicure (NASDAQ: XCUR) flags going concern, legal and listing risks  Stock Titan

Exicure (NASDAQ: XCUR) flags going concern, legal and listing risks - Stock Titan

Click here to get full coverage on Exicure (Nasdaq: XCUR) reports positive Phase 2 burixafor data in multiple myeloma - Stock Titan

Exicure (Nasdaq: XCUR) reports positive Phase 2 burixafor data in multiple myeloma  Stock Titan

Exicure (Nasdaq: XCUR) reports positive Phase 2 burixafor data in multiple myeloma - Stock Titan

Click here to get full coverage on Phase 2 myeloma stem cell trial: burixafor sees 89.7% hit goal - Stock Titan

Phase 2 myeloma stem cell trial: burixafor sees 89.7% hit goal  Stock Titan

Phase 2 myeloma stem cell trial: burixafor sees 89.7% hit goal - Stock Titan

Click here to get full coverage on Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements - BioSpace

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements  BioSpace

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements - BioSpace

Click here to get full coverage on Exicure Stock Rockets 70% on Clinical Trials, BlackRock Still In - Gotrade

Exicure Stock Rockets 70% on Clinical Trials, BlackRock Still In  Gotrade

Exicure Stock Rockets 70% on Clinical Trials, BlackRock Still In - Gotrade

Click here to get full coverage on Exicure Announces New CEO and Interim CFO Appointments - theglobeandmail.com

Exicure Announces New CEO and Interim CFO Appointments  theglobeandmail.com

Exicure Announces New CEO and Interim CFO Appointments - theglobeandmail.com

Click here to get full coverage on Exicure 10-K: Revenue $0.0M, EPS $(0.79) — net loss narrows to $(4.95)M - tradingview.com

Exicure 10-K: Revenue $0.0M, EPS $(0.79) — net loss narrows to $(4.95)M  tradingview.com

Exicure 10-K: Revenue $0.0M, EPS $(0.79) — net loss narrows to $(4.95)M - tradingview.com

Click here to get full coverage on Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know - TechStock²

Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know  TechStock²

Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know - TechStock²

Click here to get full coverage on Exicure stock soars after positive Phase 2 data for multiple myeloma drug - Investing.com

Exicure stock soars after positive Phase 2 data for multiple myeloma drug  Investing.com

Exicure stock soars after positive Phase 2 data for multiple myeloma drug - Investing.com

Click here to get full coverage on Exicure announces board and executive changes, CEO and CFO resignations - Investing.com

Exicure announces board and executive changes, CEO and CFO resignations  Investing.com

Exicure announces board and executive changes, CEO and CFO resignations - Investing.com

Click here to get full coverage on Exicure (XCUR) Stock: Biotech Shares Surge 140% on Cancer Drug Breakthrough - Blockonomi

Exicure (XCUR) Stock: Biotech Shares Surge 140% on Cancer Drug Breakthrough  Blockonomi

Exicure (XCUR) Stock: Biotech Shares Surge 140% on Cancer Drug Breakthrough - Blockonomi

Click here to get full coverage on Futures Tread Cautiously Pre-Market As Investors Await Key Fed Decision: NVDA, XCUR, GME, CASY Among Stocks To Watch - Stocktwits

Futures Tread Cautiously Pre-Market As Investors Await Key Fed Decision: NVDA, XCUR, GME, CASY Among Stocks To Watch  Stocktwits

Futures Tread Cautiously Pre-Market As Investors Await Key Fed Decision: NVDA, XCUR, GME, CASY Among Stocks To Watch - Stocktwits

Click here to get full coverage on Exicure Announces Routine Board and Audit Committee Change - TipRanks

Exicure Announces Routine Board and Audit Committee Change  TipRanks

Exicure Announces Routine Board and Audit Committee Change - TipRanks

Click here to get full coverage on Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally - TechStock²

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally  TechStock²

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally - TechStock²

Click here to get full coverage on Exicure director Sangjin Yeo resigns from board and audit committee - Investing.com

Exicure director Sangjin Yeo resigns from board and audit committee  Investing.com

Exicure director Sangjin Yeo resigns from board and audit committee - Investing.com

Click here to get full coverage on Exicure Stock Soars 40% After Stem Cell Drug Helps Most Patients Hit Phase 2 Goal — Traders Call It ‘Cheap’ At Current Levels - Stocktwits

Exicure Stock Soars 40% After Stem Cell Drug Helps Most Patients Hit Phase 2 Goal — Traders Call It ‘Cheap’ At Current Levels  Stocktwits

Exicure Stock Soars 40% After Stem Cell Drug Helps Most Patients Hit Phase 2 Goal — Traders Call It ‘Cheap’ At Current Levels - Stocktwits

Click here to get full coverage on Exicure reports positive Phase 2 results for multiple myeloma therapy - Investing.com

Exicure reports positive Phase 2 results for multiple myeloma therapy  Investing.com

Exicure reports positive Phase 2 results for multiple myeloma therapy - Investing.com

Click here to get full coverage on Exicure, Inc. Reports Full Year 2025 Financial Results - Bitget

Exicure, Inc. Reports Full Year 2025 Financial Results  Bitget

Exicure, Inc. Reports Full Year 2025 Financial Results - Bitget

Click here to get full coverage on Exicure HiTron sells shares worth $1.16 million - Investing.com

Exicure HiTron sells shares worth $1.16 million  Investing.com

Exicure HiTron sells shares worth $1.16 million - Investing.com

Click here to get full coverage on Exicure’s Smart Money Exodus Signals No Near-Term Value in a Vanishing Cash Runway - Bitget

Exicure’s Smart Money Exodus Signals No Near-Term Value in a Vanishing Cash Runway  Bitget

Exicure’s Smart Money Exodus Signals No Near-Term Value in a Vanishing Cash Runway - Bitget

Click here to get full coverage on Curate Price Today | XCUR to USD Live Price, Market Cap & Chart - Binance

Curate Price Today | XCUR to USD Live Price, Market Cap & Chart  Binance

Curate Price Today | XCUR to USD Live Price, Market Cap & Chart - Binance

Click here to get full coverage on Curate (XCUR) Price Today: XCUR Live Price, Charts, News - Crypto.com

Curate (XCUR) Price Today: XCUR Live Price, Charts, News  Crypto.com

Curate (XCUR) Price Today: XCUR Live Price, Charts, News - Crypto.com

Click here to get full coverage on Exicure, Inc. Files Form 8-K with SEC – Company Info, Stock Symbol XCUR, and NASDAQ Listing Details - Minichart

Exicure, Inc. Files Form 8-K with SEC – Company Info, Stock Symbol XCUR, and NASDAQ Listing Details  Minichart

Exicure, Inc. Files Form 8-K with SEC – Company Info, Stock Symbol XCUR, and NASDAQ Listing Details - Minichart

Click here to get full coverage on Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - Business Wire

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)  Business Wire

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - Business Wire

Click here to get full coverage on Exicure’s Stunning Rise: What’s Fueling It? - StocksToTrade

Exicure’s Stunning Rise: What’s Fueling It?  StocksToTrade

Exicure’s Stunning Rise: What’s Fueling It? - StocksToTrade

Click here to get full coverage on Top Gainers on the US Stock Market Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and More Surge as Fed Meeting Looms - TechStock²

Top Gainers on the US Stock Market Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and More Surge as Fed Meeting Looms  TechStock²

Top Gainers on the US Stock Market Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and More Surge as Fed Meeting Looms - TechStock²

Click here to get full coverage on This BlackRock stock just rocketed 70% - Finbold

This BlackRock stock just rocketed 70%  Finbold

This BlackRock stock just rocketed 70% - Finbold

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Latest XCUR News - Exicure, Inc. Reports Full Year 2025 Financ... - Stock Titan

Latest XCUR News - Exicure, Inc. Reports Full Year 2025 Financ...  Stock Titan

Latest XCUR News - Exicure, Inc. Reports Full Year 2025 Financ... - Stock Titan

Click here to get full coverage on After ‘Improprieties,’ Exicure to Wind Down XCUR-FXN Program - Friedreich's Ataxia News

After ‘Improprieties,’ Exicure to Wind Down XCUR-FXN Program  Friedreich's Ataxia News

After ‘Improprieties,’ Exicure to Wind Down XCUR-FXN Program - Friedreich's Ataxia News

Click here to get full coverage on EXICURE, INC. SEC 10-K Report - tradingview.com

EXICURE, INC. SEC 10-K Report  tradingview.com

EXICURE, INC. SEC 10-K Report - tradingview.com

Click here to get full coverage on Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes - Stocktwits

Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes  Stocktwits

Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes - Stocktwits

Click here to get full coverage on XCUR Stock Price and Chart — NASDAQ:XCUR - tradingview.com

XCUR Stock Price and Chart — NASDAQ:XCUR  tradingview.com

XCUR Stock Price and Chart — NASDAQ:XCUR - tradingview.com

Click here to get full coverage on Exicure Stock Price Forecast. Should You Buy XCUR? - StockInvest.us

Exicure Stock Price Forecast. Should You Buy XCUR?  StockInvest.us

Exicure Stock Price Forecast. Should You Buy XCUR? - StockInvest.us

Click here to get full coverage on Exicure, Inc. (XCUR) stock price, news, quote and history - Yahoo Finance Singapore

Exicure, Inc. (XCUR) stock price, news, quote and history  Yahoo Finance Singapore

Exicure, Inc. (XCUR) stock price, news, quote and history - Yahoo Finance Singapore

Click here to get full coverage on Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results - Business Wire

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results  Business Wire

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results - Business Wire

Click here to get full coverage on Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech - Business Wire

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech  Business Wire

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech - Business Wire

Click here to get full coverage on Curate price today, XCUR to USD live price, marketcap and chart - CoinMarketCap

Curate price today, XCUR to USD live price, marketcap and chart  CoinMarketCap

Curate price today, XCUR to USD live price, marketcap and chart - CoinMarketCap

Click here to get full coverage on ST: KuCoin Will Delist Certain Projects and Their Associated Tokens - KuCoin

ST: KuCoin Will Delist Certain Projects and Their Associated Tokens  KuCoin

ST: KuCoin Will Delist Certain Projects and Their Associated Tokens - KuCoin

Click here to get full coverage on Bill Gates Slashes Investment in This Penny Biotech Stock - Barron's

Bill Gates Slashes Investment in This Penny Biotech Stock  Barron's

Bill Gates Slashes Investment in This Penny Biotech Stock - Barron's

Click here to get full coverage on KuCoin Will Support the BEP20 Curate (XCUR) Token Migration - KuCoin

KuCoin Will Support the BEP20 Curate (XCUR) Token Migration  KuCoin

KuCoin Will Support the BEP20 Curate (XCUR) Token Migration - KuCoin

Click here to get full coverage on DGP Co. Ltd. purchases $711k of Exicure shares at $3 each - Investing.com UK

DGP Co. Ltd. purchases $711k of Exicure shares at $3 each  Investing.com UK

DGP Co. Ltd. purchases $711k of Exicure shares at $3 each - Investing.com UK

Click here to get full coverage on Cbi Usa, Inc. Net Worth (2026) - GuruFocus

Cbi Usa, Inc. Net Worth (2026)  GuruFocus

Cbi Usa, Inc. Net Worth (2026) - GuruFocus

Click here to get full coverage on Exicure (XCUR) Stock: Biotech Soars on Promising Cancer Drug Data - parameter.io

Exicure (XCUR) Stock: Biotech Soars on Promising Cancer Drug Data  parameter.io

Exicure (XCUR) Stock: Biotech Soars on Promising Cancer Drug Data - parameter.io

Click here to get full coverage on Exicure (XCUR) Stock Live Price, Chart & News - CoinCodex

Exicure (XCUR) Stock Live Price, Chart & News  CoinCodex

XCUR

Price Chart

Key Statistics

Technicals

About XCUR

Latest News

XCUR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Exicure (NASDAQ: XCUR) advances derivative case settlement with new governance controls - Stock Titan

Insider Sale: 10% owner at $XCUR Sells 433,332 Shares | XCUR Stock News - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers